Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond TARGETING PI3Kδ in CLL

Saved in:
Bibliographic Details
Published inMedicinal research reviews Vol. 35; no. 4; pp. 720 - 752
Main Authors Wei, Manman, Wang, Xiang, Song, Zilan, Jiao, Mingkun, Ding, Jian, Meng, Ling-Hua, Zhang, Ao
Format Journal Article
LanguageEnglish
Published 01.07.2015
Online AccessGet full text

Cover

Author Song, Zilan
Wei, Manman
Wang, Xiang
Zhang, Ao
Meng, Ling-Hua
Ding, Jian
Jiao, Mingkun
Author_xml – sequence: 1
  givenname: Manman
  surname: Wei
  fullname: Wei, Manman
  organization: CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 2
  givenname: Xiang
  surname: Wang
  fullname: Wang, Xiang
  organization: Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 3
  givenname: Zilan
  surname: Song
  fullname: Song, Zilan
  organization: CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 4
  givenname: Mingkun
  surname: Jiao
  fullname: Jiao, Mingkun
  organization: CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 5
  givenname: Jian
  surname: Ding
  fullname: Ding, Jian
  organization: Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 6
  givenname: Ling-Hua
  surname: Meng
  fullname: Meng, Ling-Hua
  organization: Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
– sequence: 7
  givenname: Ao
  surname: Zhang
  fullname: Zhang, Ao
  organization: CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM); Chinese Academy of Sciences; Shanghai 201203 China
BookMark eNrjYmDJy89LZWAQNDTQMzQwMNLPTU3RMzI0NjFkYeA0MLS00DUzNjLlYOAqLs4yMDA0NDU05mTwC0ksSk8tycxLVwjwNPY-t8VKwTU3tSgdJBCSkVqUWFCpkJZfpOCcUZSfl5ms4FOZW5CRn1xZAmKnlman5mYmKiTmpSg4pVbm56XwMLCmJeYUp_JCaW4GTTfXEGcP3eSi_OLiotS0-IKizNzEosp4Q4N4kCPjgY6MBzvSmBS1AFPWRxE
Cites_doi 10.1158/1535-7163.MCT-08-1200
10.1517/13543776.2012.701281
10.2174/092986711796011193
10.1016/S0140-6736(07)61125-8
10.1016/j.cell.2006.03.035
10.1038/nrc1753
10.1021/ml200156t
10.1158/2159-8290.CD-NB2013-177
10.1182/blood-2011-06-338855
10.1158/0008-5472.CAN-09-4355
10.1248/bpb.32.297
10.1016/j.bmcl.2010.10.021
10.3324/haematol.2009.007849
10.2174/156802609789044434
10.1016/j.pharmthera.2014.07.003
10.1200/JCO.2008.20.8389
10.1073/pnas.94.9.4330
10.1016/S0021-9258(17)37680-9
10.1042/bj2960297
10.1021/jm300717c
10.1021/jm300679u
10.1182/blood-2007-09-111781
10.1080/10428190600555819
10.1038/nrclinonc.2013.10
10.1186/1756-8722-6-88
10.1016/S0006-291X(03)01480-3
10.1182/blood.V17.2.182.182
10.1200/JCO.2007.12.9098
10.1038/nrc839
10.1021/jm3003747
10.2147/OTT.S3099
10.1038/nature13444
10.1038/nchembio.293
10.1016/j.bmcl.2007.02.032
10.1200/JCO.2010.27.9836
10.1016/S0021-9258(17)41900-4
10.1021/jm901284w
10.1021/jm051056c
10.1016/j.molimm.2004.04.008
10.1126/science.296.5573.1655
10.2174/092986709788803222
10.1016/S0021-9258(18)45857-7
10.1158/1078-0432.CCR-11-1402
10.1038/nrd2926
10.1016/S0007-1536(57)80033-3
10.1517/13543776.2014.865725
10.1126/science.1073560
10.1182/blood-2005-04-1718
10.1038/nri955
10.1038/aps.2013.81
10.1182/blood-2004-03-0796
10.1016/j.tibs.2009.01.003
10.1056/NEJMra041720
10.1182/blood-2010-07-296913
10.1016/j.bmcl.2007.12.018
10.1016/j.hoc.2012.12.003
10.1021/jm800295d
10.1021/jm2009327
10.1056/NEJMoa1313984
10.1128/MCB.16.4.1722
10.1182/blood-2008-02-140582
10.1038/nrd4204
10.1007/s11899-013-0189-7
10.1158/1535-7163.MCT-08-0017
10.1016/j.bmcl.2012.05.027
10.1038/leu.2011.12
10.1016/S0968-0004(97)01061-X
10.1371/journal.pone.0025132
10.18632/oncotarget.2533
10.1136/bmj.2.4949.1172
10.1021/ml1001932
10.1038/bjc.2011.450
10.1128/MCB.22.24.8580-8591.2002
10.1158/2159-8290.CD-11-0249
10.1200/JCO.2008.21.1128
10.1016/j.bmcl.2013.06.052
10.14694/EdBook_AM.2012.32.89
10.1021/jm4003632
10.1182/blood-2010-02-271171
10.1016/j.clinthera.2013.08.004
10.1016/j.semcancer.2010.08.004
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1002/med.21341
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EndPage 752
ExternalDocumentID 10_1002_med_21341
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAYXX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
CITATION
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
GWYGA
H.X
HBH
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
SAMSI
SUPJJ
SV3
UB1
V8K
W8V
W99
WBFHL
WBKPD
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WWP
WXI
WXSBR
WYISQ
XG1
XV2
YCJ
ZGI
ZZTAW
~IA
~WT
ID FETCH-crossref_primary_10_1002_med_213413
ISSN 0198-6325
IngestDate Fri Aug 23 01:10:15 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-crossref_primary_10_1002_med_213413
ParticipantIDs crossref_primary_10_1002_med_21341
PublicationCentury 2000
PublicationDate 2015-07-00
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-00
PublicationDecade 2010
PublicationTitle Medicinal research reviews
PublicationYear 2015
References Chiorazzi (10.1002/med.21341-BIB0005|med21341-cit-0005) 2005; 352
Sadhu (10.1002/med.21341-BIB0072|med21341-cit-0072) 2003
Shaw (10.1002/med.21341-BIB0009|med21341-cit-0009) 1961; 17
Coutre (10.1002/med.21341-BIB0087|med21341-cit-0087) 2011; 29
Wang (10.1002/med.21341-BIB0082|med21341-cit-0082) 2014; 5
10.1002/med.21341-BIB0001|med21341-cit-0001
Tam (10.1002/med.21341-BIB0021|med21341-cit-0021) 2008; 112
Evarts (10.1002/med.21341-BIB0075|med21341-cit-0075) 2013
Desmond-Hellman (10.1002/med.21341-BIB0089|med21341-cit-0089) 2014; 4
Chang (10.1002/med.21341-BIB0043|med21341-cit-0043) 2014; 9
Kong (10.1002/med.21341-BIB0053|med21341-cit-0053) 2009; 32
10.1002/med.21341-BIB0088|med21341-cit-0088
Danilov (10.1002/med.21341-BIB0007|med21341-cit-0007) 2013; 35
Goede (10.1002/med.21341-BIB0017|med21341-cit-0017) 2014; 370
Ciraolo (10.1002/med.21341-BIB0037|med21341-cit-0037) 2011; 18
Knight (10.1002/med.21341-BIB0054|med21341-cit-0054) 2006; 125
Knauf (10.1002/med.21341-BIB0010|med21341-cit-0010) 2009; 27
Fruman (10.1002/med.21341-BIB0069|med21341-cit-0069) 2014; 13
Akinleye (10.1002/med.21341-BIB0038|med21341-cit-0038) 2013; 6
Fowler (10.1002/med.21341-BIB0073|med21341-cit-0073) 2005
Roper (10.1002/med.21341-BIB0060|med21341-cit-0060) 2011; 6
Powis (10.1002/med.21341-BIB0047|med21341-cit-0047) 1994; 54
Dal Porto (10.1002/med.21341-BIB0025|med21341-cit-0025) 2004; 41
Raynaud (10.1002/med.21341-BIB0064|med21341-cit-0064) 2009; 8
Norman (10.1002/med.21341-BIB0091|med21341-cit-0091) 2012; 22
Cheson (10.1002/med.21341-BIB0016|med21341-cit-0016) 2010; 28
Burger (10.1002/med.21341-BIB0057|med21341-cit-0057) 2011; 2
Ten Hacken (10.1002/med.21341-BIB0024|med21341-cit-0024) 2014; 144
Niiro (10.1002/med.21341-BIB0022|med21341-cit-0022) 2002; 2
Workman (10.1002/med.21341-BIB0033|med21341-cit-0033) 2012
Byrd (10.1002/med.21341-BIB0020|med21341-cit-0020) 2005; 105
Fruman (10.1002/med.21341-BIB0045|med21341-cit-0045) 2011; 1
Brian (10.1002/med.21341-BIB0046|med21341-cit-0046) 1957; 40
Herman (10.1002/med.21341-BIB0042|med21341-cit-0042) 2012; 18
Kok (10.1002/med.21341-BIB0032|med21341-cit-0032) 2009; 34
Nakanishi (10.1002/med.21341-BIB0050|med21341-cit-0050) 1992; 267
White (10.1002/med.21341-BIB0074|med21341-cit-0074) 2008
Coscia (10.1002/med.21341-BIB0094|med21341-cit-0094) 2011; 25
Ali (10.1002/med.21341-BIB0081|med21341-cit-0081) 2014; 510
Palanki (10.1002/med.21341-BIB0068|med21341-cit-0068) 2007; 50
Vanhaesebroeck (10.1002/med.21341-BIB0029|med21341-cit-0029) 1997; 22
Murray (10.1002/med.21341-BIB0078|med21341-cit-0078) 2012; 55
Smith (10.1002/med.21341-BIB0003|med21341-cit-0003) 2011; 105
Cantley (10.1002/med.21341-BIB0028|med21341-cit-0028) 2002; 296
Liu (10.1002/med.21341-BIB0035|med21341-cit-0035) 2009; 8
Safina (10.1002/med.21341-BIB0080|med21341-cit-0080) 2013; 23
Berndt (10.1002/med.21341-BIB0092|med21341-cit-0092) 2010; 6
Norman (10.1002/med.21341-BIB0090|med21341-cit-0090) 2014; 24
Coiffier (10.1002/med.21341-BIB0014|med21341-cit-0014) 2008; 111
Flinn (10.1002/med.21341-BIB0084|med21341-cit-0084) 2009; 114
Stevenson (10.1002/med.21341-BIB0023|med21341-cit-0023) 2011; 118
Folkes (10.1002/med.21341-BIB0063|med21341-cit-0063) 2008; 51
Safina (10.1002/med.21341-BIB0077|med21341-cit-0077) 2012; 55
Sutherlin (10.1002/med.21341-BIB0065|med21341-cit-0065) 2010; 53
Alduaij (10.1002/med.21341-BIB0018|med21341-cit-0018) 2011; 117
Molica (10.1002/med.21341-BIB0004|med21341-cit-0004) 2006; 47
Okkenhaug (10.1002/med.21341-BIB0040|med21341-cit-0040) 2002; 297
Okada (10.1002/med.21341-BIB0048|med21341-cit-0048) 1994; 269
Galton (10.1002/med.21341-BIB0008|med21341-cit-0008) 1955; 2
Stauffer (10.1002/med.21341-BIB0058|med21341-cit-0058) 2008; 18
Stephens (10.1002/med.21341-BIB0027|med21341-cit-0027) 2013; 27
Sadhu (10.1002/med.21341-BIB0071|med21341-cit-0071) 2003; 308
Richardson (10.1002/med.21341-BIB0093|med21341-cit-0093) 2006; 107
Vivanco (10.1002/med.21341-BIB0030|med21341-cit-0030) 2002; 2
Sutherlin (10.1002/med.21341-BIB0066|med21341-cit-0066) 2011; 54
Arcaro (10.1002/med.21341-BIB0049|med21341-cit-0049) 1993; 296
Rodon (10.1002/med.21341-BIB0070|med21341-cit-0070) 2013; 10
Ndubaku (10.1002/med.21341-BIB0061|med21341-cit-0061) 2013; 56
Bader (10.1002/med.21341-BIB0031|med21341-cit-0031) 2005; 5
Pecchi (10.1002/med.21341-BIB0056|med21341-cit-0056) 2010; 20
Hayakawa (10.1002/med.21341-BIB0062|med21341-cit-0062) 2007; 17
Herman (10.1002/med.21341-BIB0076|med21341-cit-0076) 2010; 116
Schweighofer (10.1002/med.21341-BIB0019|med21341-cit-0019) 2010; 3
Sutherlin (10.1002/med.21341-BIB0079|med21341-cit-0079) 2012; 22
Wang (10.1002/med.21341-BIB0083|med21341-cit-0083) 2013; 34
Hillmen (10.1002/med.21341-BIB0013|med21341-cit-0013) 2007; 25
Turiso (10.1002/med.21341-BIB0067|med21341-cit-0067) 2012; 55
Vlahos (10.1002/med.21341-BIB0052|med21341-cit-0052) 1994; 269
Webb (10.1002/med.21341-BIB0086|med21341-cit-0086) 2010; 116
Jou (10.1002/med.21341-BIB0041|med21341-cit-0041) 2002; 22
Ameriks (10.1002/med.21341-BIB0044|med21341-cit-0044) 2009; 9
Workman (10.1002/med.21341-BIB0034|med21341-cit-0034) 2010; 70
Kristinsson (10.1002/med.21341-BIB0002|med21341-cit-0002) 2009; 94
Catovsky (10.1002/med.21341-BIB0011|med21341-cit-0011) 2007; 370
Maira (10.1002/med.21341-BIB0059|med21341-cit-0059) 2008; 7
Wymann (10.1002/med.21341-BIB0051|med21341-cit-0051) 1996; 16
Cramer (10.1002/med.21341-BIB0006|med21341-cit-0006) 2010; 10
Jain (10.1002/med.21341-BIB0012|med21341-cit-0012) 2012; 26
Vanhaesebroeck (10.1002/med.21341-BIB0039|med21341-cit-0039) 1997; 94
Packhama (10.1002/med.21341-BIB0026|med21341-cit-0026) 2010; 20
Burger (10.1002/med.21341-BIB0055|med21341-cit-0055) 2011; 2
Stilgenbauer (10.1002/med.21341-BIB0015|med21341-cit-0015) 2009; 27
Kong (10.1002/med.21341-BIB0036|med21341-cit-0036) 2009; 16
Sharman (10.1002/med.21341-BIB0085|med21341-cit-0085) 2011; 118
References_xml – volume: 8
  start-page: 1725
  issue: 7
  year: 2009
  ident: 10.1002/med.21341-BIB0064|med21341-cit-0064
  article-title: Biological properties of potent inhibitors of class-phosphatidylinositol-3-kinases: From Pi-103 through Pi-540,Pi-620 to the oral agent GDC-0941
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-1200
  contributor:
    fullname: Raynaud
– volume: 22
  start-page: 965
  year: 2012
  ident: 10.1002/med.21341-BIB0091|med21341-cit-0091
  article-title: Evaluation of WO2012032067 and WO2012055846, two selective PI3Kδ inhibitor, which is GSK-2269557
  publication-title: Expert Opin Ther Pat
  doi: 10.1517/13543776.2012.701281
  contributor:
    fullname: Norman
– volume: 18
  start-page: 2674
  year: 2011
  ident: 10.1002/med.21341-BIB0037|med21341-cit-0037
  article-title: Present and future of PI3K pathway inhibition in cancer: Perspectives and limitations
  publication-title: Curr Med Chem
  doi: 10.2174/092986711796011193
  contributor:
    fullname: Ciraolo
– volume: 370
  start-page: 230
  issue: 9583
  year: 2007
  ident: 10.1002/med.21341-BIB0011|med21341-cit-0011
  article-title: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61125-8
  contributor:
    fullname: Catovsky
– volume: 125
  start-page: 733
  year: 2006
  ident: 10.1002/med.21341-BIB0054|med21341-cit-0054
  article-title: Pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
  publication-title: Cell
  doi: 10.1016/j.cell.2006.03.035
  contributor:
    fullname: Knight
– ident: 10.1002/med.21341-BIB0088|med21341-cit-0088
– volume: 5
  start-page: 921
  issue: 12
  year: 2005
  ident: 10.1002/med.21341-BIB0031|med21341-cit-0031
  article-title: Oncogenic PI3K deregulates transcription and translation
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1753
  contributor:
    fullname: Bader
– volume: 2
  start-page: 774
  year: 2011
  ident: 10.1002/med.21341-BIB0055|med21341-cit-0055
  article-title: Identification of NVP-BKM120 as a potent, selective, orally bioavailable class-PI3 kinase inhibitor for treating cancer
  publication-title: ACS Med Chem Lett
  doi: 10.1021/ml200156t
  contributor:
    fullname: Burger
– volume: 4
  start-page: 136
  year: 2014
  ident: 10.1002/med.21341-BIB0089|med21341-cit-0089
  article-title: IPI-145 shows promise in CLL patients
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-NB2013-177
  contributor:
    fullname: Desmond-Hellman
– volume: 118
  start-page: 4313
  issue: 16
  year: 2011
  ident: 10.1002/med.21341-BIB0023|med21341-cit-0023
  article-title: B-cell receptor signaling in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2011-06-338855
  contributor:
    fullname: Stevenson
– volume: 70
  start-page: 2146
  issue: 6
  year: 2010
  ident: 10.1002/med.21341-BIB0034|med21341-cit-0034
  article-title: Drugging the PI3 kinome: From chemical tools to drugs in the clinic
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-4355
  contributor:
    fullname: Workman
– volume: 32
  start-page: 297
  year: 2009
  ident: 10.1002/med.21341-BIB0053|med21341-cit-0053
  article-title: Effect of ZSTK474, a novel phosphatidylinositol-3-kinase inhibitor, on DNA-dependent protein kinase
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.32.297
  contributor:
    fullname: Kong
– volume: 20
  start-page: 6895
  year: 2010
  ident: 10.1002/med.21341-BIB0056|med21341-cit-0056
  article-title: Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2010.10.021
  contributor:
    fullname: Pecchi
– volume: 94
  start-page: 1259
  year: 2009
  ident: 10.1002/med.21341-BIB0002|med21341-cit-0002
  article-title: Improved survival in chronic lymphocytic leukemia in the past decade: A population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
  publication-title: Haematologia
  doi: 10.3324/haematol.2009.007849
  contributor:
    fullname: Kristinsson
– volume: 9
  start-page: 738
  year: 2009
  ident: 10.1002/med.21341-BIB0044|med21341-cit-0044
  article-title: Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ
  publication-title: Curr Top Med Chem
  doi: 10.2174/156802609789044434
  contributor:
    fullname: Ameriks
– volume: 144
  start-page: 338
  issue: 3
  year: 2014
  ident: 10.1002/med.21341-BIB0024|med21341-cit-0024
  article-title: Microenvironment dependency in chronic lymphocytic leukemia: The basis for new targeted therapies
  publication-title: Pharm Ther
  doi: 10.1016/j.pharmthera.2014.07.003
  contributor:
    fullname: Ten Hacken
– year: 2005
  ident: 10.1002/med.21341-BIB0073|med21341-cit-0073
  article-title: Quinazolinones as inhibitors of human phosphatidylinositol-3-kinase delta
  publication-title: PCT International Application
  contributor:
    fullname: Fowler
– volume: 27
  start-page: 4378
  issue: 26
  year: 2009
  ident: 10.1002/med.21341-BIB0010|med21341-cit-0010
  article-title: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.8389
  contributor:
    fullname: Knauf
– volume: 94
  start-page: 4330
  year: 1997
  ident: 10.1002/med.21341-BIB0039|med21341-cit-0039
  article-title: p110d, a novel phosphoinositide 3-kinase in leukocytes
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.94.9.4330
  contributor:
    fullname: Vanhaesebroeck
– volume: 269
  start-page: 5241
  year: 1994
  ident: 10.1002/med.21341-BIB0052|med21341-cit-0052
  article-title: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran -4-one (LY294002)
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)37680-9
  contributor:
    fullname: Vlahos
– volume: 296
  start-page: 297
  issue: Pt 2
  year: 1993
  ident: 10.1002/med.21341-BIB0049|med21341-cit-0049
  article-title: Wortmannin is a potent phosphatidylinositol-3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses
  publication-title: Biochem J
  doi: 10.1042/bj2960297
  contributor:
    fullname: Arcaro
– volume: 55
  start-page: 7686
  year: 2012
  ident: 10.1002/med.21341-BIB0078|med21341-cit-0078
  article-title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta
  publication-title: J Med Chem
  doi: 10.1021/jm300717c
  contributor:
    fullname: Murray
– volume: 55
  start-page: 7667
  year: 2012
  ident: 10.1002/med.21341-BIB0067|med21341-cit-0067
  article-title: Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors
  publication-title: J Med Chem
  doi: 10.1021/jm300679u
  contributor:
    fullname: Turiso
– volume: 111
  start-page: 1094
  issue: 3
  year: 2008
  ident: 10.1002/med.21341-BIB0014|med21341-cit-0014
  article-title: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
  publication-title: Blood
  doi: 10.1182/blood-2007-09-111781
  contributor:
    fullname: Coiffier
– year: 2013
  ident: 10.1002/med.21341-BIB0075|med21341-cit-0075
  article-title: Compositions and methods of treating a disease with (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrine
  publication-title: PCT International Application
  contributor:
    fullname: Evarts
– volume: 47
  start-page: 1477
  year: 2006
  ident: 10.1002/med.21341-BIB0004|med21341-cit-0004
  article-title: Sex differences in incidence and outcome of chronic lymphocytic leukemia patients
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190600555819
  contributor:
    fullname: Molica
– volume: 10
  start-page: 143
  year: 2013
  ident: 10.1002/med.21341-BIB0070|med21341-cit-0070
  article-title: Development of PI3K inhibitors: Lessons learned from early clinical trials
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2013.10
  contributor:
    fullname: Rodon
– volume: 6
  start-page: 88
  year: 2013
  ident: 10.1002/med.21341-BIB0038|med21341-cit-0038
  article-title: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
  publication-title: J Hetatol Oncol
  doi: 10.1186/1756-8722-6-88
  contributor:
    fullname: Akinleye
– volume: 308
  start-page: 764
  issue: 4
  year: 2003
  ident: 10.1002/med.21341-BIB0071|med21341-cit-0071
  article-title: Selective role of PI3K delta in neutrophil inflammatory responses
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/S0006-291X(03)01480-3
  contributor:
    fullname: Sadhu
– volume: 114
  start-page: 922
  issue: 22
  year: 2009
  ident: 10.1002/med.21341-BIB0084|med21341-cit-0084
  article-title: Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110δ isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies
  publication-title: ASH Ann Meet Abstr
  contributor:
    fullname: Flinn
– volume: 17
  start-page: 182
  year: 1961
  ident: 10.1002/med.21341-BIB0009|med21341-cit-0009
  article-title: A study of prednisone therapy in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V17.2.182.182
  contributor:
    fullname: Shaw
– volume: 25
  start-page: 5616
  issue: 35
  year: 2007
  ident: 10.1002/med.21341-BIB0013|med21341-cit-0013
  article-title: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.12.9098
  contributor:
    fullname: Hillmen
– volume: 2
  start-page: 489
  issue: 7
  year: 2002
  ident: 10.1002/med.21341-BIB0030|med21341-cit-0030
  article-title: The phosphatidylinositol 3-kinase AKT pathway in human cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc839
  contributor:
    fullname: Vivanco
– volume: 55
  start-page: 5887
  year: 2012
  ident: 10.1002/med.21341-BIB0077|med21341-cit-0077
  article-title: Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: Taming CYP3A4 time-dependent inhibition
  publication-title: J Med Chem
  doi: 10.1021/jm3003747
  contributor:
    fullname: Safina
– volume: 29
  issue: S6631
  year: 2011
  ident: 10.1002/med.21341-BIB0087|med21341-cit-0087
  article-title: Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with previously treated chronic lymphocytic leukemia
  publication-title: J Clin Oncol
  contributor:
    fullname: Coutre
– volume: 3
  start-page: 53
  year: 2010
  ident: 10.1002/med.21341-BIB0019|med21341-cit-0019
  article-title: First-line treatment of chronic lymphocytic leukemia: Role of alemtuzumab
  publication-title: Oncol Targets Ther
  doi: 10.2147/OTT.S3099
  contributor:
    fullname: Schweighofer
– volume: 510
  start-page: 407
  issue: 7505
  year: 2014
  ident: 10.1002/med.21341-BIB0081|med21341-cit-0081
  article-title: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
  publication-title: Nature
  doi: 10.1038/nature13444
  contributor:
    fullname: Ali
– year: 2008
  ident: 10.1002/med.21341-BIB0074|med21341-cit-0074
  article-title: Thienopyrimidinones for treatment of inflammatory disorders and cancers
  publication-title: PCT International Application
  contributor:
    fullname: White
– volume: 26
  start-page: 1067
  issue: 11
  year: 2012
  ident: 10.1002/med.21341-BIB0012|med21341-cit-0012
  article-title: Chronic lymphocytic leukemia with deletion 17p: Emerging treatment options
  publication-title: Oncology
  contributor:
    fullname: Jain
– volume: 54
  start-page: 2419
  year: 1994
  ident: 10.1002/med.21341-BIB0047|med21341-cit-0047
  article-title: Wortmannin, a potent and selective inhibitor of PI3K
  publication-title: Cancer Res
  contributor:
    fullname: Powis
– volume: 6
  start-page: 117
  year: 2010
  ident: 10.1002/med.21341-BIB0092|med21341-cit-0092
  article-title: The p110-structure: Mechanisms for selectivity and potency of new PI3K inhibitors
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.293
  contributor:
    fullname: Berndt
– volume: 17
  start-page: 2438
  year: 2007
  ident: 10.1002/med.21341-BIB0062|med21341-cit-0062
  article-title: Synthesis and biological evaluation of pyrido[3’,2’:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110a inhibitors
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2007.02.032
  contributor:
    fullname: Hayakawa
– volume: 28
  start-page: 3525
  issue: 21
  year: 2010
  ident: 10.1002/med.21341-BIB0016|med21341-cit-0016
  article-title: Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.27.9836
  contributor:
    fullname: Cheson
– volume: 269
  start-page: 3563
  year: 1994
  ident: 10.1002/med.21341-BIB0048|med21341-cit-0048
  article-title: Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol-3-kinase
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)41900-4
  contributor:
    fullname: Okada
– volume: 53
  start-page: 1086
  year: 2010
  ident: 10.1002/med.21341-BIB0065|med21341-cit-0065
  article-title: Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer
  publication-title: J Med Chem
  doi: 10.1021/jm901284w
  contributor:
    fullname: Sutherlin
– volume: 50
  start-page: 4279
  year: 2007
  ident: 10.1002/med.21341-BIB0068|med21341-cit-0068
  article-title: Discovery of 3,3‘-(2,4-diaminopteridine-6,7-diyl) diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction
  publication-title: J Med Chem
  doi: 10.1021/jm051056c
  contributor:
    fullname: Palanki
– volume: 41
  start-page: 599
  issue: 16
  year: 2004
  ident: 10.1002/med.21341-BIB0025|med21341-cit-0025
  article-title: B cell antigen receptor signaling 101
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2004.04.008
  contributor:
    fullname: Dal Porto
– volume: 296
  start-page: 1655
  year: 2002
  ident: 10.1002/med.21341-BIB0028|med21341-cit-0028
  article-title: The phosphoinositide 3-kinase pathway
  publication-title: Science
  doi: 10.1126/science.296.5573.1655
  contributor:
    fullname: Cantley
– volume: 16
  start-page: 2839
  year: 2009
  ident: 10.1002/med.21341-BIB0036|med21341-cit-0036
  article-title: Advances in development of phosphatidylinositol 3-kinase inhibitors
  publication-title: Curr Med Chem
  doi: 10.2174/092986709788803222
  contributor:
    fullname: Kong
– volume: 267
  start-page: 2157
  year: 1992
  ident: 10.1002/med.21341-BIB0050|med21341-cit-0050
  article-title: Wortmannin, a microbial product inhibitor of myosin light chain kinase
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)45857-7
  contributor:
    fullname: Nakanishi
– volume: 18
  start-page: 4013
  year: 2012
  ident: 10.1002/med.21341-BIB0042|med21341-cit-0042
  article-title: Molecular pathways: Targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1402
  contributor:
    fullname: Herman
– volume: 8
  start-page: 627
  year: 2009
  ident: 10.1002/med.21341-BIB0035|med21341-cit-0035
  article-title: Targeting the phosphoinositide 3-kinase pathway in cancer
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2926
  contributor:
    fullname: Liu
– volume: 40
  start-page: 365
  year: 1957
  ident: 10.1002/med.21341-BIB0046|med21341-cit-0046
  article-title: Wortmannin, an antibiotic produced by penicillium wortmanni
  publication-title: Trans Br Mycol Soc
  doi: 10.1016/S0007-1536(57)80033-3
  contributor:
    fullname: Brian
– volume: 24
  start-page: 471
  year: 2014
  ident: 10.1002/med.21341-BIB0090|med21341-cit-0090
  article-title: Evaluation of WO2013136076, two crystalline forms of the PI3K inhibitor RV-1729
  publication-title: Expert Opin Ther Pat
  doi: 10.1517/13543776.2014.865725
  contributor:
    fullname: Norman
– volume: 297
  start-page: 1031
  year: 2002
  ident: 10.1002/med.21341-BIB0040|med21341-cit-0040
  article-title: Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice
  publication-title: Science
  doi: 10.1126/science.1073560
  contributor:
    fullname: Okkenhaug
– ident: 10.1002/med.21341-BIB0001|med21341-cit-0001
– volume: 118
  start-page: 1787
  issue: 21
  year: 2011
  ident: 10.1002/med.21341-BIB0085|med21341-cit-0085
  article-title: A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
  publication-title: ASH Ann Meet Abstr
  contributor:
    fullname: Sharman
– volume: 10
  start-page: 37
  year: 2010
  ident: 10.1002/med.21341-BIB0006|med21341-cit-0006
  article-title: Prognostic factors in chronic lymphocytic leukemia-What do we need to know
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Cramer
– volume: 107
  start-page: 3584
  issue: 9
  year: 2006
  ident: 10.1002/med.21341-BIB0093|med21341-cit-0093
  article-title: ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)
  publication-title: Blood
  doi: 10.1182/blood-2005-04-1718
  contributor:
    fullname: Richardson
– volume: 2
  start-page: 945
  issue: 12
  year: 2002
  ident: 10.1002/med.21341-BIB0022|med21341-cit-0022
  article-title: Regulation of B-cell fate by antigen-receptor signals
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri955
  contributor:
    fullname: Niiro
– volume: 34
  start-page: 1201
  issue: 9
  year: 2013
  ident: 10.1002/med.21341-BIB0083|med21341-cit-0083
  article-title: A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2013.81
  contributor:
    fullname: Wang
– volume: 105
  start-page: 49
  year: 2005
  ident: 10.1002/med.21341-BIB0020|med21341-cit-0020
  article-title: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
  publication-title: Blood
  doi: 10.1182/blood-2004-03-0796
  contributor:
    fullname: Byrd
– volume: 34
  start-page: 115
  issue: 3
  year: 2009
  ident: 10.1002/med.21341-BIB0032|med21341-cit-0032
  article-title: Regulation of phosphoinositide 3-kinase expression in health and disease
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2009.01.003
  contributor:
    fullname: Kok
– volume: 352
  start-page: 804
  issue: 8
  year: 2005
  ident: 10.1002/med.21341-BIB0005|med21341-cit-0005
  article-title: Mechanisms of disease: Chronic lymphocytic leukemia
  publication-title: N Eng J Med
  doi: 10.1056/NEJMra041720
  contributor:
    fullname: Chiorazzi
– volume: 117
  start-page: 4519
  issue: 17
  year: 2011
  ident: 10.1002/med.21341-BIB0018|med21341-cit-0018
  article-title: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
  publication-title: Blood
  doi: 10.1182/blood-2010-07-296913
  contributor:
    fullname: Alduaij
– volume: 18
  start-page: 1027
  year: 2008
  ident: 10.1002/med.21341-BIB0058|med21341-cit-0058
  article-title: Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2007.12.018
  contributor:
    fullname: Stauffer
– volume: 27
  start-page: 303
  year: 2013
  ident: 10.1002/med.21341-BIB0027|med21341-cit-0027
  article-title: Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy
  publication-title: Hematol Oncol Clin North Am
  doi: 10.1016/j.hoc.2012.12.003
  contributor:
    fullname: Stephens
– volume: 51
  start-page: 5522
  year: 2008
  ident: 10.1002/med.21341-BIB0063|med21341-cit-0063
  article-title: The identification of 2-(1H-indazol-4-yl)-6-(4-methane sulfonyl-piperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
  publication-title: J Med Chem
  doi: 10.1021/jm800295d
  contributor:
    fullname: Folkes
– volume: 54
  start-page: 7579
  year: 2011
  ident: 10.1002/med.21341-BIB0066|med21341-cit-0066
  article-title: Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer
  publication-title: J Med Chem
  doi: 10.1021/jm2009327
  contributor:
    fullname: Sutherlin
– volume: 370
  start-page: 1101
  issue: 12
  year: 2014
  ident: 10.1002/med.21341-BIB0017|med21341-cit-0017
  article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1313984
  contributor:
    fullname: Goede
– volume: 16
  start-page: 1722
  year: 1996
  ident: 10.1002/med.21341-BIB0051|med21341-cit-0051
  article-title: Wortmannin inactivates phosphatidylinositol-3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.16.4.1722
  contributor:
    fullname: Wymann
– volume: 112
  start-page: 975
  year: 2008
  ident: 10.1002/med.21341-BIB0021|med21341-cit-0021
  article-title: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2008-02-140582
  contributor:
    fullname: Tam
– volume: 13
  start-page: 140
  year: 2014
  ident: 10.1002/med.21341-BIB0069|med21341-cit-0069
  article-title: PI3K and cancer: Lessons, challenges and opportunities
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4204
  contributor:
    fullname: Fruman
– volume: 9
  start-page: 33
  year: 2014
  ident: 10.1002/med.21341-BIB0043|med21341-cit-0043
  article-title: PI3-kinase inhibitors in chronic lymphocytic leukemia
  publication-title: Curr Hematol Malig Rep
  doi: 10.1007/s11899-013-0189-7
  contributor:
    fullname: Chang
– year: 2003
  ident: 10.1002/med.21341-BIB0072|med21341-cit-0072
  article-title: Inhibitors of human phosphatidylinositol 3-kinase delta
  publication-title: PCT International Application
  contributor:
    fullname: Sadhu
– volume: 7
  start-page: 1851
  year: 2008
  ident: 10.1002/med.21341-BIB0059|med21341-cit-0059
  article-title: Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTOR inhibitor with potent in vivo antitumor activity
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0017
  contributor:
    fullname: Maira
– volume: 22
  start-page: 4296
  year: 2012
  ident: 10.1002/med.21341-BIB0079|med21341-cit-0079
  article-title: Potent and selective inhibitors of PI3Kd: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmcl.2012.05.027
  contributor:
    fullname: Sutherlin
– volume: 25
  start-page: 828
  issue: 5
  year: 2011
  ident: 10.1002/med.21341-BIB0094|med21341-cit-0094
  article-title: IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
  publication-title: Leukemia
  doi: 10.1038/leu.2011.12
  contributor:
    fullname: Coscia
– volume: 22
  start-page: 267
  issue: 7
  year: 1997
  ident: 10.1002/med.21341-BIB0029|med21341-cit-0029
  article-title: Phosphoinositide 3-kinases: A conserved family of signal transducers
  publication-title: Trends Biochem Sci
  doi: 10.1016/S0968-0004(97)01061-X
  contributor:
    fullname: Vanhaesebroeck
– volume: 6
  start-page: e25132
  issue: 9
  year: 2011
  ident: 10.1002/med.21341-BIB0060|med21341-cit-0060
  article-title: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0025132
  contributor:
    fullname: Roper
– volume: 5
  start-page: 10732
  issue: 21
  year: 2014
  ident: 10.1002/med.21341-BIB0082|med21341-cit-0082
  article-title: Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2533
  contributor:
    fullname: Wang
– volume: 2
  start-page: 1172
  year: 1955
  ident: 10.1002/med.21341-BIB0008|med21341-cit-0008
  article-title: Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB1348) in malignant lymphoma
  publication-title: Br Med J
  doi: 10.1136/bmj.2.4949.1172
  contributor:
    fullname: Galton
– volume: 2
  start-page: 34
  year: 2011
  ident: 10.1002/med.21341-BIB0057|med21341-cit-0057
  article-title: Synthesis and in vitro and in vivo evaluation of phosphatidylinositol-3-kinase inhibitors
  publication-title: ACS Med Chem Lett
  doi: 10.1021/ml1001932
  contributor:
    fullname: Burger
– volume: 105
  start-page: 1684
  issue: 11
  year: 2011
  ident: 10.1002/med.21341-BIB0003|med21341-cit-0003
  article-title: Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.450
  contributor:
    fullname: Smith
– volume: 22
  start-page: 8580
  year: 2002
  ident: 10.1002/med.21341-BIB0041|med21341-cit-0041
  article-title: Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.22.24.8580-8591.2002
  contributor:
    fullname: Jou
– volume: 1
  start-page: 562
  issue: 7
  year: 2011
  ident: 10.1002/med.21341-BIB0045|med21341-cit-0045
  article-title: PI3Kdelta inhibitors in cancer: Rationale and serendipity merge in the clinic
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-11-0249
  contributor:
    fullname: Fruman
– volume: 27
  start-page: 3994
  issue: 24
  year: 2009
  ident: 10.1002/med.21341-BIB0015|med21341-cit-0015
  article-title: Leukemia and bone marrow transplantation subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.21.1128
  contributor:
    fullname: Stilgenbauer
– volume: 23
  start-page: 4953
  year: 2013
  ident: 10.1002/med.21341-BIB0080|med21341-cit-0080
  article-title: Identification of GNE-293, a potent and selective PI3Kd inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2013.06.052
  contributor:
    fullname: Safina
– start-page: e93
  year: 2012
  ident: 10.1002/med.21341-BIB0033|med21341-cit-0033
  article-title: PI3 kinase in cancer: From biology to clinic
  publication-title: Am Soc Clin Oncol Educ Book
  doi: 10.14694/EdBook_AM.2012.32.89
  contributor:
    fullname: Workman
– volume: 56
  start-page: 4597
  year: 2013
  ident: 10.1002/med.21341-BIB0061|med21341-cit-0061
  article-title: Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl) -5,6-dihydrobenzo[f] imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2- methylpropanamide (GDC-0032): A β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
  publication-title: J Med Chem
  doi: 10.1021/jm4003632
  contributor:
    fullname: Ndubaku
– volume: 116
  start-page: 2078
  issue: 12
  year: 2010
  ident: 10.1002/med.21341-BIB0076|med21341-cit-0076
  article-title: Phosphatidylinositol-3 -kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic signals
  publication-title: Blood
  doi: 10.1182/blood-2010-02-271171
  contributor:
    fullname: Herman
– volume: 35
  start-page: 1258
  issue: 9
  year: 2013
  ident: 10.1002/med.21341-BIB0007|med21341-cit-0007
  article-title: Targeted therapy in chronic lymphocytic leukemia: Past, present, and future
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2013.08.004
  contributor:
    fullname: Danilov
– volume: 20
  start-page: 391
  issue: 6
  year: 2010
  ident: 10.1002/med.21341-BIB0026|med21341-cit-0026
  article-title: The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2010.08.004
  contributor:
    fullname: Packhama
– volume: 116
  start-page: 1774
  issue: 21
  year: 2010
  ident: 10.1002/med.21341-BIB0086|med21341-cit-0086
  article-title: Clinical pharmacokinetics of CAL-101, a p110δ isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies
  publication-title: ASH Ann Meet Abstr
  contributor:
    fullname: Webb
SSID ssj0011513
Score 4.3218627
SourceID crossref
SourceType Aggregation Database
StartPage 720
Subtitle TARGETING PI3Kδ in CLL
Title Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bTsJAEN0ovvhivMZ7NkZIDBShV-ubEgwqEmJqJL4QCltCkGIUHup3-R1-k9Od7W4jJqIvTdt0S8M5nZ2ZnTkl5NgPum5P933Nck2mmYFpay6zylpgGobF_B64_bzKt2HXHsybltVS9fO8u2TiF7vvP_aV_AdVOAe4xl2yf0BW3hROwD7gC1tAGLbzYczLuONgv3lt3GYr1eylGYf4caaJf3zIQ80AXksoZHDz9QgAHHejWKm1zqZDNsK-rDw2s6S91TtceOfa_yI9ItRL1YLOADt-wpGi2aPIQbeAen2ZwhG1v0-DZ3XlzaAzxuL9sD-chukURNmS5aoyK-meabaBHcyJWUUVEkEfM2UjHb2Umm4dFLCdseSoDAseQZFrzqnpKlmi_zaLydpC1GHW2zC0zYcukiUdrBBfw7-X2mLgCeO3s5NnT2SnSvqp_NWUs5LyOrxVsiLCBXqB2K-RBRauk1wT9cajAvVU-9xbgeZoUymRRxukIQlCY4J8fpzThBpiZESBGlRQg6aoQRNqUKAGRWpskpOrqlepacnTtl9Qq6Q9828YWyQTjkO2TahTDhyDGS6DkBkC307HhrcUbL7L4ADe3R1y9Pv9due5aI8sK97sk8zkdcoOwJmb-IcclC-6Hk_d
link.rule.ids 315,783,787,27936,27937
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+PI3K%CE%B4%3A+Emerging+Therapy+for+Chronic+Lymphocytic+Leukemia+and+Beyond&rft.jtitle=Medicinal+research+reviews&rft.au=Wei%2C+Manman&rft.au=Wang%2C+Xiang&rft.au=Song%2C+Zilan&rft.au=Jiao%2C+Mingkun&rft.date=2015-07-01&rft.issn=0198-6325&rft.volume=35&rft.issue=4&rft.spage=720&rft.epage=752&rft_id=info:doi/10.1002%2Fmed.21341&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_med_21341
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0198-6325&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0198-6325&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0198-6325&client=summon